Tom Popper

Featured in: Favicon

medium.com Favicon

bio.news

Articles

What BIO’s watching in the 119th Congress

Jan 27, 2025 | bio.news | Tom Popper

Reforms to prevent middlemen from driving up drug prices and legislation encouraging the development of oral medications and rare disease treatments were called top priorities as the Biotechnology Innovation Organization (BIO) began work with a new Congress. The 119th Congress could also pass tax breaks for R&D and many other measures supportive of biotech innovation, according to Aiken Hackett, BIO’s SVP of Federal Government Relations.
Multi-billion-dollar deals at JPM Week augur a busy BIO CEO 2025

Jan 19, 2025 | bio.news | Tom Popper

The year in biotech M&A activity got off to a promising start at JPM Week with announcements of some multi-billion-dollar deals. The flurry of networking in San Francisco between Jan. 13-16 also highlighted some of the trends that are likely to be hot topics as partnering activity continues at the next big biotech gathering, the Feb. 10-11 BIO CEO & Investor Conference in New York.
Buzz around JPM Week partnering bodes well for biotech dealmaking, BIO says

Jan 10, 2025 | bio.news | Tom Popper

The increased interest in JPM Week this year is an indication of an improved dealmaking environment for biotech, according to experts for the Biotechnology Innovation Organization (BIO) who are helping to drive partnering at the event. Before the Jan.
BIO applauds panel’s ruling to halt Mexico biotech corn ban

Jan 5, 2025 | bio.news | Tom Popper

A dispute panel ruled that Mexico’s planned ban on imports of biotech corn is “not based on relevant scientific principles” and would violate the U.S.-Mexico-Canada Agreement (USMCA). The Biotechnology Innovation Organization (BIO) hailed it as a victory. BIO was one of only a handful of non-government entities (NGEs) asked to brief the dispute panel—and the only NGE speaking in support of the U.S.’s science-based position. BIO President & CEO John F. Crowley praised the Dec. 20 decision.
How BIO's comments affected regulations on genetically engineered crops

Jan 5, 2025 | bio.news | Tom Popper

Federal officials said they withdrew plans for new regulation of genetically engineered (GE) crops on U.S. wildlife refuges due to the outcry by numerous stakeholders, including the Biotechnology Innovation Organization (BIO). The U.S. Fish and Wildlife Service (FWS) acknowledged the impact of public comments in their Dec.
BIO CEO John F. Crowley calls for innovation in access

Nov 15, 2024 | bio.news | Tom Popper

As biotech breakthroughs enable remarkable advances in treatment and prevention of disease, we need similar levels of innovation in access, so patients benefit from these breakthroughs, John F. Crowley, President & CEO of the Biotechnology Innovation Organization (BIO), told the Milken Institute’s Future of Health Summit. During a Nov.
BIO Investor Forum panel breaks down when, what, and why of IPOs

Oct 17, 2024 | bio.news | Tom Popper

Biotech firms weighing an initial public offering (IPO) must consider timing, interest in their product, the macro environment—and whether they really need all the headaches, according to an Oct. 16 BIO Investor Forum panel. “Why do you want to go public? It’s not a super-fun experience,” said Colin Walsh, Managing Director, Growth Equity at Goldman Sachs.
BIO Investor Forum opens with encouraging news on financing

Oct 16, 2024 | bio.news | Tom Popper

The tide has been rising in biotech investment in 2024—though it has not lifted all boats equally. While the volume of investment improved in the first half of 2024, much of it went to a few “mega deals,” leaving many promising small biotechs still seeking funding, according to data presented during the Oct. 15 opening panel of the 2024 BIO Investor Forum in San Francisco, hosted by the Biotechnology Innovation Organization (BIO).
Colorado price-setting board conflicts with federal law, BIO tells court

Oct 13, 2024 | bio.news | Tom Popper

Colorado’s efforts to impose price controls on prescription drugs are preempted by federal law, according to a legal brief by the Biotechnology Innovation Organization (BIO). Colorado’s approach presents a threat to both innovation and patient access, particularly for rare disease patients, the brief, filed Sept. 13, explains.
Sen. Cassidy calls on FDA to act, not abdicate, on drug device patents

Oct 7, 2024 | bio.news | Tom Popper

Food and Drug Administration (FDA) inaction on patents for drug delivery devices has been troubling drug manufacturers for 20 years, and the situation is getting worse, says Sen. Bill Cassidy, MD (R-La). Now the FDA is committing “an extraordinary abdication of authority,” allowing Federal Trade Commission (FTC) intervention that burdens the industry, Cassidy writes in a Sept.